<DOC>
	<DOCNO>NCT00639054</DOCNO>
	<brief_summary>Observational study investigate prognostic factor newly diagnose relapse multiple myeloma patient use clinical data , biochemical marker ( blood sample ) , cytogenetic marker gene expression profile ( myeloma cell fresh bone marrow sample ) . Enabling future genetic study establish biobank bone marrow peripheral blood sample .</brief_summary>
	<brief_title>The Molecular Characterization Multiple Myeloma Relapse</brief_title>
	<detailed_description>Multiple myeloma ( MM ) incurable cancer . The disease often bring halt chemotherapy young patient accompanied stem cell transplantation . But disease relapse almost invariably . Cytogenetic change myeloma cell serve prognostic marker . Accordingly , 25 % patient show change associate prognosis poor probably receive experimental treatment right start . Nevertheless , part patient survive much longer expect . Thus , prognosis must depend additional genetic event . The aim project widen investigator knowledge nature , chronology prognostic value genetic event MM order improve risk stratification patient hence choice treatment . Using cytogenetics ( interphase FISH ) molecular biological analysis ( SNP , GEP , miRNA ) investigator study change myeloma cell . The investigator search genetic clinical difference patient within cytogenetic group patient diagnosis relapse . The study population consist 100 newly diagnose patient 100 relapse patient include prospectively 2-year period cooperation four department hematology Zealand , Denmark . Hypotheses : 1 . Early relapse depend ) molecular defect myeloma cell detectable FISH , GEP , SNP and/or miRNA analysis , b ) acquisition new mutation result chemotherapy resistance increase prolific capacity . 2 . The progressive reduction event free survival see every relapse disease turn refractory explain selection critical mutation . 3 . The cytogenetic change associate poor prognosis represent heterogenous group patient responsible genetic event remain unknown .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>patient newly diagnose multiple myeloma time eligible high dose chemotherapy autologous stem cell transplantation patient multiple myeloma experience relapse high dose chemotherapy autologous stem cell transplantation newly diagnose patient : age comorbidity prevent high dose chemotherapy autologous stem cell transplantation , patient : age 18 , physical psychological incapability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>classification</keyword>
	<keyword>diagnosis</keyword>
	<keyword>genetics</keyword>
	<keyword>mortality</keyword>
	<keyword>pathology</keyword>
</DOC>